Regulatory Effects and Mechanism of Immune Inhibitory Receptor LAIR-1 in Non-small Cell Lung Cancer
Author:
Yu Shuo1, Yu Ruoxi1, Liu Dan2, Song Weikang1, Duan Xuming1, Sun Deyu1, Qu Yanli1
Affiliation:
1. Liaoning Cancer Hospital & Institute 2. Fourth Affiliated Hospital of China Medical University
Abstract
Abstract
Purpose To investigate the association of leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) levels with clinicopathological features and prognosis of non-small cell lung cancer (NSCLC).
Methods The expression of LAIR-1 and clinicopathological data were downloaded from The Cancer Genome Atlas database and Gene Expression Omnibus for analyzing the correlation between LAIR-1 expression and prognosis. Tissue samples from 118 NSCLC patients and 47 paired adjacent cancer tissues were collected and the expression of LAIR-1 in NSCLC tissues was detected by immunohistochemistry. The statistical analysis was performed for association analysis of LAIR-1 expression and clinicopathological properties. Lentiviral transfection of NSCLC cell lines A549 and SK-MES-1 for overexpressing LAIR-1 were used to evaluate the role of LAIR-1 in regulating cell cycle and apoptosis in NSCLC cell lines by flow cytometry.
Results LAIR-1 expression was lower in NSCLC tissues than in para-cancerous tumor tissues, and overall survival time was lower in the LAIR-1 low- expression group. Univariate analysis revealed that the low expression of LAIR-1 was related to lymph node metastasis, tumor stage, etc. in NSCLC patients. The LAIR-1 low-expression group of the NSCLC patients showed higher mortality, tumor progression, and lower overall survival and disease-free survival. Multivariate analyses demonstrated that the expression of LAIR-1 in squamous carcinoma patients had a negative correlation with NSCLC progression. In vitro experiments showed that the overexpression of LAIR-1 blocked the squamous cell carcinoma at the G1 stage and promoted cell apoptosis.
Conclusion LAIR-1 was closely associated with lymph node metastasis, tumor stage, and patients’ prognosis.
Publisher
Research Square Platform LLC
Reference20 articles.
1. Cao, Q., Fu, A., Yang, S., He, X., Wang, Y., Zhang, X., Zhou, J., Luan, X., Yu, W., and Xue, J. (2015). Leukocyte-associated immunoglobulin-like receptor-1 expressed in epithelial ovarian cancer cells and involved in cell proliferation and invasion. Biochem Biophys Res Commun 458: 399–404.https://doi.org/10.1016/j.bbrc.2015.01.127 2. Cheng, J. C., Chou, C. H., Kuo, M. L., and Hsieh, C. Y. (2006). Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25: 7009–7018.https://doi.org/10.1038/sj.onc.1209706 3. Fumarola, C., Bonelli, M. A., Petronini, P. G., and Alfieri, R. R. (2014). Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol 90: 197–207.https://doi.org/10.1016/j.bcp.2014.05.011 4. Guo, N., Zhang, K., Gao, X., Lv, M., Luan, J., Hu, Z., Li, A., and Gou, X. (2020). Role and mechanism of LAIR-1 in the development of autoimmune diseases, tumors, and malaria: A review. Curr Res Transl Med 68: 119–124.https://doi.org/10.1016/j.retram.2020.05.003 5. Joseph, C., Alsaleem, M. A., Toss, M. S., Kariri, Y. A., Althobiti, M., Alsaeed, S., Aljohani, A. I., Narasimha, P. L., Mongan, N. P., Green, A. R., and Rakha, E. A. (2020). The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma. Cancers (Basel) 13: 80.https://doi.org/10.3390/cancers13010080
|
|